<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Minocycline (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Minocycline (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Minocycline (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="123041" href="/d/html/123041.html" rel="external">see "Minocycline (topical): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="122966" href="/d/html/122966.html" rel="external">see "Minocycline (topical): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53872298"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amzeeq;</li>
<li>Zilxi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53763465"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acne Products;</li>
<li>
                        Antibiotic, Tetracycline Derivative;</li>
<li>
                        Topical Skin Product, Acne</li></ul></div>
<div class="block doa drugH1Div" id="F53912380"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot use first-line agents. Use in combination with benzoyl peroxide to reduce the risk for the development of antibiotic resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-Graber.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-Graber.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical:</b> Foam 4% (Amzeeq): Express a small (cherry-sized) amount to fingertips and apply to acne-affected areas once daily; may repeat until all acne-affected areas are treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30165171','lexi-content-ref-31163231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30165171','lexi-content-ref-31163231'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc3a2a3a-842f-4019-92f3-0d78d87a74b9">Rosacea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rosacea: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical:</b> Foam 1.5% (Zilxi): Express a small (cherry-sized) amount to fingertips and apply a thin layer to all areas of the face once daily; may repeat until entire face is covered.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53912382"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F53912383"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F53912381"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53802835"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="122966" href="/d/html/122966.html" rel="external">see "Minocycline (topical): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris: Note:</b> Due to emerging resistance patterns, topical antibiotics should not typically be used as monotherapy for the management of acne vulgaris (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225','lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225','lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years and Adolescents: Topical: Foam 4% (Amzeeq): Apply small amount (eg, cherry sized) to affected area(s) once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F53803201"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F53803202"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F53766332"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of skin (≤13%), erythema of skin (≤36%), exfoliation of skin (≤16%), hyperpigmentation (≤23%), pruritus (≤20%), stinging of skin (≤13%), telangiectasia (19% to 61%), xeroderma (≤24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Flushing sensation (≤39%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3%)</p></div>
<div class="block coi drugH1Div" id="F53763468"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tetracyclines or to any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53912373"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune syndromes: Lupus-like, hepatitis, and vasculitis autoimmune syndromes (including serum sickness [eg, fever, arthralgia, malaise]) have been reported with oral minocycline; immediately discontinue if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Lightheadedness, dizziness, and vertigo have been reported with oral minocycline; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). Symptoms may disappear with continued therapy and when the drug is discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic failure (sometimes fatal), have been reported with oral minocycline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/Skin reaction: Anaphylaxis, rash, erythema multiforme, Stevens Johnson syndrome or eosinophilia, fever, and organ failure including death (drug rash with eosinophilia and systemic symptoms [DRESS] syndrome), have been reported with oral minocycline; discontinue treatment immediately if DRESS syndrome is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intracranial hypertension: Intracranial hypertension (eg, headache, blurred vision, diplopia, vision loss, papilledema) has been associated with use of tetracyclines. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Concomitant use of isotretinoin (known to cause intracranial hypertension) and minocycline should be avoided. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patients until they stabilize.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic effects: May be associated with increases in BUN secondary to antianabolic effects of tetracyclines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Photosensitivity has been reported with oral tetracyclines. Although not reported with topical minocycline, use skin protection, wear loose-fitting clothes that protect skin from sun exposure, and avoid or minimize exposure to natural or artificial sunlight. Discontinue use at first evidence of sunburn.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile–</i>associated diarrhea (CDAD) and pseudomembranous colitis, has been reported with prolonged use of oral minocycline; CDAD has been observed &gt;2 months post antibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration have been reported with oral tetracyclines, more common with long-term use, but observed with repeated, short courses. Use of tetracyclines should be avoided during tooth development (infancy and children ≤8 years of age) unless other drugs are not likely to be effective or are contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Flammable contents: Foam contains flammable propellants. Avoid fire, flame, and smoking during and immediately following application.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Acne: The American Academy of Dermatology acne guidelines generally recommend topical antibiotics be used in conjunction with other therapies (not as monotherapy) due to the risk of bacterial resistance (AAD [Zaenglein 2016]).</p></div>
<div class="block prod-avail drugH1Div" id="F54438263"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Zilxi (minocycline 1.5% topical foam): FDA approved May 2020; anticipated availability in the fourth quarter of 2020.</p></div>
<div class="block foc drugH1Div" id="F53872299"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amzeeq: 4% (30 g) [contains cetostearyl alcohol, coconut oil (copra/cocos nucifera oil), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zilxi: 1.5% (30 g) [contains cetostearyl alcohol, coconut oil (copra/cocos nucifera oil), soybean oil]</p></div>
<div class="block geq drugH1Div" id="F53872297"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53880545"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Amzeeq External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $19.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Zilxi External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5% (per gram): $19.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F53912384"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Topical: Not for oral, ophthalmic, or intravaginal use. Shake can well before use. Allow can to warm to room temperature before first use. Apply at approximately the same time each day ≥1 hour before bedtime. Do not bathe, shower, or swim for ≥1 hour after application. Avoid fire, flame, or smoking during or immediately following application.</p></div>
<div class="block admp drugH1Div" id="F53803398"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: Foam: For topical external use only; not for oral, ophthalmic, or intravaginal use. Prior to treatment, thoroughly wash affected area(s) with mild cleanser and pat dry. Allow product to reach room temperature prior to first use. Shake can well before use; express foam from can onto fingertips and then gently rub on acne-affected area(s). Apply at the same time each day, at least 1 hour before bedtime; do not bathe, shower, or swim for at least 1 hour after application. Avoid fire, flame, or smoking during or immediately following application.</p></div>
<div class="block use drugH1Div" id="F53763467"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b> Foam 4% (Amzeeq): Topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients ≥9 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rosacea:</b> Foam 1.5% (Zilxi): Topical treatment of inflammatory lesions of rosacea in adults.</p></div>
<div class="block mst drugH1Div" id="F53912368"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Amzeeq may be confused with Amitiza, Belviq, Pristiq.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53808788"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53808785"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F53912370"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Minocycline crosses the placenta and may cause fetal harm following oral administration. The amount of minocycline available systemically is less following topical application than with oral use. As a class, tetracyclines should be avoided during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the Minocycline (Systemic) monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F53912372"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if minocycline is present in breast milk following topical administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline is present in breast milk following oral administration. However, the amount of minocycline available systemically is less following topical application than with oral administration. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to the Minocycline (Systemic) monograph for additional information.</p></div>
<div class="block pha drugH1Div" id="F53912377"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanism of action of minocycline for the treatment of acne or rosacea is unknown.</p></div>
<div class="block phk drugH1Div" id="F53912378"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Topical: Acne: Steady-state reached after 6 days; pediatric patients (10 to &lt;17 years of age) had a 2.4-fold higher C<sub>max</sub> and a 2.7-fold higher AUC than adult patients. Rosacea: Steady-state reached by day 1.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58846819"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Minym</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Amzeeq.1">
<a name="Amzeeq.1"></a>Amzeeq (minocycline) [prescribing information]. Scottsdale, AZ: Journey Medical Corporation; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;131(suppl 3):S163-S186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-topical-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165171">
<a name="30165171"></a>Gold LS, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart IA. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. <i>J Am Acad Dermatol</i>. 2019;80(1):168-177. doi: 10.1016/j.jaad.2018.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-topical-drug-information/abstract-text/30165171/pubmed" id="30165171" target="_blank">30165171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.1">
<a name="Graber.1"></a>Graber E. Acne vulgaris: overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31163231">
<a name="31163231"></a>Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: a phase 3 study [published online June 1, 2019]. <i>J Am Acad Dermatol</i>. doi: 10.1016/j.jaad.2019.05.078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-topical-drug-information/abstract-text/31163231/pubmed" id="31163231" target="_blank">31163231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol</i>. 2016;74(5):945-973. doi: 10.1016/j.jaad.2015.12.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-topical-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zilxi.1">
<a name="Zilxi.1"></a>Zilxi (minocycline) [prescribing information]. Bridgewater, NJ: VYNE Pharmaceuticals Inc; September 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 122964 Version 66.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
